Literature DB >> 35972520

Good clinical outcomes can be expected after meniscal allograft transplantation at 15 years of follow-up.

Raúl Torres-Claramunt1,2, Rodolfo Morales-Avalos3,4, Simone Perelli1,2, José Ramón Padilla-Medina5, Joan Carles Monllau1,2.   

Abstract

PURPOSE: The aim of this study was to evaluate graft survivorship and report the functional and radiographic results of Meniscal allograft transplantation (MAT) throughout a minimum 15-year follow-up period.
METHODS: Fifty-one patients that had undergone an isolated MAT procedure during the period studied were included. The results were assessed with the Lysholm and Tegner scores as well as the Visual Analog Scale. Magnetic resonance imaging and a complete radiographic series were carried out to determine the degree of meniscal extrusion and joint space narrowing. A comparison was made between the radiological findings of the last follow-up, the 5-year mid-term follow-up and those from the preoperative period.
RESULTS: Thirty-eight patients were available for the final follow-up. The mean follow-up was 17.4 years. There were 23 (60.5%) medial menisci and 15 lateral menisci (39.4%). Meniscal extrusion increased from the 29.7% ± 14.9 obtained at the 5-year follow-up to the 72.5% ± 22.5 seen at the end of the follow-up (p = 0.0001). The joint space distance was almost unchanged from the initial evaluation (3.3 ± 1.5 mm) to the 5-year follow-up measurement (3.1 ± 1.7 mm, n.s.). However, it did decrease at the last follow-up (1.9 ± 1.5 mm, p < 0.05). The functional outcomes improved from the preoperative period to the mid-term follow-up and later worsened at the final follow-up. The mean preoperative Lysholm score at the initial follow-up was 61.5 ± 9.6, 86.9 ± 10.9 for the 5-year evaluation and stood at 77.4 ± 11.5 (p = 0.0001) at the final follow-up. Regarding the Tegner score, those pre-operative scores were compared to the ones at the last follow-up (median: 3; range 0-6 vs. 5.5; 3-6, respectively; p = 0.0001). The VAS went down from 6.6 ± 1.7 at the initial evaluation to 2.5 ± 1.9 at the final follow-up (p = 0.0001). The joint-space width remained unchanged from the initial evaluation (3.35 ± 1.5 mm) up to the 5-year follow-up measurement (3.1 ± 1.7 mm, n.s.). However, this joint-space distance had decreased by the last evaluation in the long-term follow-up (1.9 ± 1.4 mm, p < 0.05). Five patients (13.1%) presented with a MAT failure at 5 years, which was followed by extirpation of the meniscal graft. At the final follow-up, a total of 16 patients (42.1%) presented with a failure. At that time, there were 4 more MAT removals and seven patients that required a total knee replacement. The mean time to failure of the meniscal graft was 206.2 months ± 13.4 (18.0 years).
CONCLUSIONS: Meniscal allograft transplantation produces good functional results at a minimum 15-year follow-up. However, degenerative arthritis in the affected compartment progressed during that period. LEVEL OF EVIDENCE: III.
© 2022. The Author(s) under exclusive licence to European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA).

Entities:  

Keywords:  Lateral meniscus; Long term follow-up; Medial meniscus; Meniscal extrusion; Meniscal transplantation

Year:  2022        PMID: 35972520     DOI: 10.1007/s00167-022-07106-z

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.114


  1 in total

1.  The effect of lumbar spinal fusion on native acetabular anteinclination in standing position.

Authors:  Dimitris Dimitriou; Samuel Haupt; Sabrina Weber; Elin Winkler; Michael Betz; Mazda Farshad
Journal:  Arch Orthop Trauma Surg       Date:  2022-06-29       Impact factor: 3.067

  1 in total
  1 in total

1.  Meniscus allograft transplantation for biologic knee preservation: gold standard or dilemma?

Authors:  Janina Kaarre; Zachary J Herman; Bálint Zsidai; Alberto Grassi; Stefano Zaffagnini; Kristian Samuelsson; Volker Musahl
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2022-10-07       Impact factor: 4.114

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.